Debu Tripathy, MD,

Articles

Dr. Tripathy on Targeting HER2 in Breast Cancer

July 31st 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

May 3rd 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Dr. Tripathy on Maintenance Therapy in Breast Cancer

April 12th 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses maintenance therapy for patients with breast cancer.

Dr. Tripathy on 10 Versus 5 Years of Adjuvant Tamoxifen

February 12th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the ATLAS trial that compared 5 years of adjuvant tamoxifen to 10 in patients with estrogen receptor-positive early breast cancer.

Dr. Debu Tripathy Reviews the Phase III CONFIRM Trial

February 4th 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the final analysis of overall survival for the phase III CONFIRM trial.

Dr. Debu Tripathy on the CDK4/6 Inhibitor PD 0332991

January 11th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Dr. Debu Tripathy Previews the Phase II GRN1005 Study

November 14th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined GRN1005 in patients with brain metastases from breast cancer.

Dr. Tripathy on the Updated EMILIA T-DM1 Trial Results

October 15th 2012

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Dr. Tripathy Discusses Breast Cancer Prevention

March 16th 2012

Dr. Debu Tripathy, from the USC Norris Comprehensive Cancer Center, Discusses Breast Cancer Prevention

Dr. Tripathy on the Miami Breast Cancer Conference

January 12th 2012

Dr. Debu Tripathy, from USC Norris Comprehensive Cancer Center, on the Miami Breast Cancer Conference

Dr. Tripathy on the AVEREL Bevacizumab Trial Results

December 9th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses the AVEREL Bevacizumab Trial Results

Dr. Tripathy Discusses Iniparib Trial Heterogeneity

October 11th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Dr. Tripathy Discusses Breast Carcinoma Heterogeneity

September 20th 2011

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Tripathy Discusses Biomarker Use in Clinical Trials

September 12th 2011

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Dr. Tripathy on Connecting Markers to Clinical Outcomes

September 1st 2011

Dr. Debu Tripathy from the USC Norris Cancer Center on Connecting Markers to Clinical Outcomes

Dr. Tripathy on Determining the Best HER2 Targeted Therapy

August 25th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on Determining the Best HER2 Targeted Therapy

Dr. Tripathy Discusses HER2 Targeted Therapies

August 22nd 2011

Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies

Dr. Tripathy on Completing New Assays After Recurrence

August 18th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Dr. Tripathy on the Future of Breast Cancer Meeting

August 16th 2011

Dr. Debu Tripathy from USC Norris Cancer Center Describes the Benefits of the PER Conferences

Dr. Tripathy on the Oncotype DX Assay Recurrence Score

August 15th 2011

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score